Do Traders Think AEterna Zentaris Inc. (AEZS) Can Keep Climbing Thursday?

The market has been high on AEterna Zentaris Inc. (AEZS) stock recently. AEZS gets a Bullish score from InvestorsObserver Stock Sentiment Indicator.

AEterna Zentaris Inc. has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on AEZS!

See Full AEZS Report

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With AEZS Stock Today?

AEterna Zentaris Inc. (AEZS) stock is trading at $5.65 as of 1:42 PM on Thursday, Aug 18, a rise of $0.47, or 9.07% from the previous closing price of $5.18. The stock has traded between $5.13 and $5.72 so far today. Volume today is more active than usual. So far 126,578 shares have traded compared to average volume of 101,049 shares.

More About AEterna Zentaris Inc.

AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland, Ireland, Denmark, and others, of which nearly all of its revenue comes from Switzerland. Click Here to get the full Stock Report for AEterna Zentaris Inc. stock.